ALX Oncology Holdings Inc. (NASDAQ:ALXO) Shares Sold by Fmr LLC

Fmr LLC cut its stake in shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) by 25.0% during the third quarter, Holdings Channel.com reports. The institutional investor owned 5,865,106 shares of the company’s stock after selling 1,949,890 shares during the quarter. Fmr LLC owned 0.11% of ALX Oncology worth $10,674,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently made changes to their positions in the stock. Connor Clark & Lunn Investment Management Ltd. grew its position in ALX Oncology by 207.4% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 83,042 shares of the company’s stock worth $151,000 after purchasing an additional 56,028 shares during the period. GSA Capital Partners LLP acquired a new stake in ALX Oncology during the 3rd quarter worth about $88,000. Los Angeles Capital Management LLC acquired a new stake in shares of ALX Oncology during the 3rd quarter valued at about $469,000. Privium Fund Management B.V. grew its position in shares of ALX Oncology by 28.2% during the 3rd quarter. Privium Fund Management B.V. now owns 509,059 shares of the company’s stock valued at $926,000 after acquiring an additional 112,093 shares during the period. Finally, SG Americas Securities LLC grew its position in shares of ALX Oncology by 33.6% during the 3rd quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock valued at $50,000 after acquiring an additional 6,888 shares during the period. 97.97% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have recently commented on ALXO. UBS Group dropped their target price on ALX Oncology from $25.00 to $4.00 and set a “buy” rating on the stock in a research report on Friday, August 16th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a research note on Tuesday, November 12th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $10.67.

Insider Buying and Selling

In related news, Director Rekha Hemrajani bought 30,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was bought at an average price of $1.55 per share, with a total value of $46,500.00. Following the completion of the transaction, the director now directly owns 33,000 shares of the company’s stock, valued at approximately $51,150. This represents a 1,000.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 33.40% of the stock is currently owned by insiders.

ALX Oncology Price Performance

ALXO opened at $1.51 on Thursday. The company has a current ratio of 4.82, a quick ratio of 4.82 and a debt-to-equity ratio of 0.07. The firm has a market cap of $79.64 million, a price-to-earnings ratio of -0.53 and a beta of 1.04. The stock’s 50-day moving average price is $1.50 and its 200 day moving average price is $3.75. ALX Oncology Holdings Inc. has a 12-month low of $1.19 and a 12-month high of $17.83.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.